Effects of Teneligliptin improvement endothelial dysfunction, inflammation, coagulation and oxidative stress in patients with coronary artery disease and diabetes, pilot study (Tiramisu study).
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Teneligliptin (Primary)
- Indications Coronary artery disease; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms Tiramisu
- 03 Jun 2017 Status changed from recruiting to discontinued.
- 10 Oct 2013 New trial record